Anthropic IPO: Voting Rights and Share Structure

Anthropic, PBC publicly filed its Form S-1 on October 26, 2026, for a proposed IPO of Class A common stock to list on the Nasdaq Global Select Market under the ticker ANT. Share count and price range are not set, and the registration statement is not yet effective. Governance is the load-bearing feature of the deal: a single non-economic Class F share, steered by a majority of the seven co-founders through a Founder LLC, is designed to cast 50.1% of the vote on matters submitted to stockholders, while an independent Long-Term Benefit Trust elects four of seven directors. Public buyers get economics, not control.

Sources below mix the company’s October 26 announcement, contemporaneous reads of the public S-1, and earlier Reuters and Wall Street Journal reviews of the draft and charter that those reads largely confirm. Where a term was not located in materials reviewed today, the table says so rather than inferring it.

Share classes and voting rights

The capital structure separates economic claims from control. Class A is the public stock (one vote per share). A single Class F share, held by a Founder LLC of the seven co-founders and carrying no economic rights, is directed by a majority of those founders and is designed to cast 50.1% of voting power on key stockholder matters, including election of some directors. That percentage is not diluted by new issuances. Strategic partners hold non-voting Class N shares (Amazon convertible notes are described as converting into Class N). Class T is the trust’s governance share. Class E, issued to non-founder employees, has no economic rights and votes only on trust-related matters, such as removing a trust-appointed director when the nominating committee disagrees or amending the trust’s rights.

Item	What the filing and prior reviews describe	Source
Classes	Five: Class A (public, 1 vote), Class F (one share, Founder LLC, 50.1% of votes, no economics), Class T (Long-Term Benefit Trust), Class N (strategic partners, no vote), Class E (employees, no economics, trust-related votes only)	[post:217], [web:25]
Who directs Class F	Majority vote inside the Founder LLC of the seven co-founders, not the CEO alone. Named members include Dario Amodei, Daniela Amodei, Tom Brown, and Chris Olah	[web:25], [web:232]
Sunset / removal	A founder can leave the LLC for quitting, death, selling too many shares, or “cause.” Public-filing reads say the 50.1% ends if fewer than three founders remain for 90 consecutive days, or if the share is redeemed or the LLC dissolves. Earlier Reuters review of the draft described a phase-out once two or fewer founders or successors remain	[post:217], [web:87]
Warning to buyers	The company has said this structure can produce decisions that conflict with stockholders’ financial interests and may hurt the value of Class A common stock	[web:30], [web:241]

Long-Term Benefit Trust

The trust is a Delaware purpose trust with the same purpose as Anthropic. It holds Class T stock with little or no economic claim. Its real power is the board: it elects and can remove without cause four of seven directors. It also gets advance notice of certain crown-jewel actions. Trustees are paid for time and are described as holding no equity, so they cannot be bought out of the mission. Weakening the trust is intentionally hard.

Power	Detail	Source
Board	Elects four of seven directors; can remove those directors without cause. Class A and Class F holders elect the other three	[web:118], [web:56], [post:217]
Notice / protective provisions	Five days’ notice before more than routine debt, a sale of half or more of the company, or transfer of control of a frontier model above thresholds the board updates quarterly. Thresholds themselves have not been public. Anthropic has said notice is not a formal veto; lawyers have noted that the removal power can function as one in practice	[web:118], [web:117]
Amendment	WSJ review of the certificate of incorporation: eliminating or diluting the trust’s power requires the trust’s own support, plus in various cases three-quarters of the board or stockholder majorities as high as 85%. A 2023 company post described stockholder-only “failsafe” supermajorities; the later charter description did not preserve an easy stockholder-only off switch	[web:118], [web:117]
Trustees	Designed as five financially disinterested trustees. Recent public counts have been lower after departures (including Mariano-Florentino Cuéllar leaving for a company role). Named figures in recent reporting include Neil Buddy Shah (chair), Ben Bernanke, and Richard Fontaine; Christopher Stubbs was added in late October	[web:57], [web:188], [web:117]

Board, PBC status, controlled-company status, anti-takeover

Upon completion of the IPO, Daniela Amodei (president and board chair), Dario Amodei, and one still-unnamed director are to be elected by Class F and Class A holders. The trust elects the other four. Because Class F already carries 50.1% of the vote on those elections, public Class A holders do not independently elect any director.

Anthropic is a Delaware public benefit corporation. Its stated public benefit is the responsible development and maintenance of advanced AI for the long-term benefit of humanity. Directors may balance stockholder returns against that purpose and the interests of people materially affected by the company’s conduct. The filing warns that this balancing can reduce the value of Class A stock.

The Founder LLC’s 50.1% voting power is the textbook fact pattern for a Nasdaq “controlled company” (more than 50% of voting power held by a person, group, or another company), which typically allows exemptions from certain board-independence listing rules. Contemporaneous commentary on the public S-1 describes buyers as entering a controlled company. An explicit “we are a controlled company” sentence was not extracted in the sources retrieved today; the voting math is what makes the status follow.

Anti-takeover protection is structural rather than a classic poison pill in the materials reviewed: non-dilutable Class F control, a trust-appointed board majority that cannot be stripped without the trust’s consent and high supermajorities, protective notice rights on debt, sale, and model transfer, and the PBC balancing duty itself.

Topic	Status	Source
Board split	7 seats: trust elects 4; Class F + Class A elect 3 (both Amodeis plus one unnamed)	[web:25], [web:56]
PBC	Remains a Delaware PBC; directors may weigh humanity’s interests alongside stockholders; filing warns of harm to Class A value	[web:117], [web:30]
Controlled company	50.1% Founder LLC vote meets the usual Nasdaq controlled-company threshold; explicit prospectus label not confirmed in sources retrieved today	[post:217], [post:267]
Anti-takeover	Multi-class control, hard-to-amend trust powers, notice rights on major transactions, PBC duty	[web:118], [web:87]

A separate, company-announced vehicle is not the trust: subject to stockholder approval, 5% of shares go to a wholly owned Anthropic Public Benefit Fund LLC, with the board able to add another 2% for every 50% increase in value above an undisclosed baseline. Equity in that LLC is not to be used for lobbying or political giving. One read of the public S-1 put the initial 5% at about 846.8 million fully diluted shares. Combined with founder and employee donation pledges, the company has said roughly 20% of shares would be dedicated to public purposes, before any escalator.

Offering terms, underwriters, proceeds, directed shares, lockups

The cover terms are still blank. Anthropic’s own announcement states that the number of Class A shares and the price range have not been determined. Pre-filing press reports of a raise as large as about $100 billion at a valuation discussed in a roughly $1.5–$2 trillion range are market expectations, not prospectus cover numbers, and should not be treated as offering terms.

Item	Status	Source
Listing	Nasdaq Global Select Market, proposed symbol ANT, Class A common stock	[web:153]
Size and price range	Not determined	[web:153]
Underwriters	Company notice names Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC as the firms from which the preliminary prospectus may be obtained. A same-day market note on the filing also lists J.P. Morgan and Citigroup in the syndicate	[web:153], [post:269]
Use of proceeds	Not quantified, because share count and price are unset. A specific allocation (compute vs. general corporate purposes vs. debt) was not available in sources retrieved today	[web:153]
Directed share / friends-and-family program	Not disclosed in the company announcement or in the S-1 reads retrieved today	—
Secondary / insider sales in the deal	Earlier reporting said the company was considering letting some existing holders sell in the IPO itself. Whether that survived into the public S-1 was not confirmed in sources retrieved today	[web:51]

Lockup terms in the public S-1, as described by readers on the day of filing, are staged rather than a single 180-day cliff. The accounts are not identical and should be checked against the prospectus underwriting section; they are consistent on the design (early partial release, longer hold for founders).

Holder group	Terms described from the public S-1	Source
Eligible directors, employees, consultants	Up to 10% of restricted shares eligible on the first trading day, and up to another 35% after 2026 annual results	[post:244]
Other holders (one read)	180 days, or release tied to the March 2027 quarter’s results	[post:131]
Founders and certain holders above 0.5%	Longer: one read says 365 days or the September 2027 quarter’s results, whichever comes first. Another says co-founders may sell up to 29% after Q1 2027 results or from day 180, subject to the prospectus conditions	[post:131], [post:244]
Earlier planning (pre-public filing)	The Information had reported consideration of day-one insider sales plus a lockup longer than the usual 180 days, and of employee sales through Rule 10b5-1 plans. Those were planning reports, not the final contract	[web:144], [web:51]

What this means for a buyer or a competitor

Public Class A stock is an economic claim on a company whose board majority is chosen by a trust with no equity stake, and whose stockholder votes on ordinary matters are outvoted by one non-economic share. Changing either mechanism requires the consent of the people who hold it, plus, on the trust, supermajorities that can reach 85%. That is the product being sold: exposure to Claude’s growth, with governance built so that safety and founder judgment can override near-term stock price. Competitors cannot copy the economics by copying the charter; the trust’s credibility depends on trustees who are paid and hold no stock, and on amendment math that public holders cannot unwind alone.

---

Recent Findings Supplement (October 2026)

Anthropic (the AI company behind Claude models) is a Delaware Public Benefit Corporation (PBC) preparing for a potential November 2026 IPO following a confidential S-1 filing on June 1, 2026 (public filing expected imminently as of late October 2026 reports). Recent disclosures and announcements (primarily September–October 2026) provide new details on its governance and mission-aligned structures, drawn from draft prospectus leaks/reports and company statements. No public S-1 yet exists with finalized offering terms.[1][2]

Information is limited to post-April 26, 2026 sources, prioritizing the most recent (e.g., October 2026 reports on filings, trustee appointments, and the Public Benefit Fund). Earlier details (pre-2026 or early 2026) on phased LTBT authority or initial trustees are omitted unless updated.

Share Class Structure and Voting Rights

Anthropic plans to maintain multi-class shares post-IPO, with founders retaining significant control via a new mechanism while the PBC and LTBT structures balance mission priorities.[3]

• New/Updated Details (Sept–Oct 2026 reports): Seven co-founders, via a Founder LLC and Class F shares, would hold 50.1% voting power on key corporate matters (including board elections) through a single controlling share; this requires stockholder approval and begins to sunset when two or fewer founders (or successors) remain. Class T shares grant the LTBT its board appointment rights. Public/Class A shareholders have limited independent say, with founders and the trust effectively directing board composition.[2][4]
• Implication for competitors/entrants: This founder super-voting + mission overlay creates a high barrier to influence via standard shareholder activism; public investors buy economic exposure with constrained governance rights.

Long-Term Benefit Trust (LTBT) and Its Powers

The LTBT is an independent oversight body (no equity ownership by trustees) designed to enforce the PBC mission of responsible AI development for humanity’s long-term benefit. Its authority has seen recent trustee updates.[5]

• New/Updated Details (July–Oct 2026): LTBT appoints/removes four of seven board directors (a majority) and receives five days’ advance notice on major actions (e.g., non-routine debt issuance, sale of ≥50% of the company, or transfer of control over frontier AI models above quarterly-updated thresholds). Trustees advise on AI risks/societal impacts and meet regularly with leadership. Current/recent trustees (as of Oct 2026): Neil Buddy Shah (chair, Clinton Health Access Initiative CEO), Ben Bernanke (former Fed Chair, appointed July 2026), Richard Fontaine (Center for a New American Security CEO), Christopher Stubbs (Harvard experimental physicist/astrophysicist, appointed Oct 21, 2026). Up to five trustees total; two seats were vacant recently (one filled by Stubbs; prior trustee Mariano-Florentino Cuéllar departed LTBT around August 2026 for a company role as chief global affairs officer). Governing documents remain non-public.[6][5][7]
• Implication: The notice provisions function similarly to protective covenants, enabling indirect veto power through board control. This structure is positioned as a potential industry model but faces scrutiny in a public setting.

Board Composition

The seven-member board splits authority between the LTBT and founder-influenced shareholders.[3]

• New/Updated Details (2026 reports): Four directors elected by LTBT (examples from coverage: Reed Hastings, Netflix co-founder; Vas Narasimhan, Novartis CEO). Three elected by Class A and Class F shareholders (with founders’ 50.1% voting influence). Recent change: Cuéllar transition noted above.[8]
• Implication: Public shareholders cannot independently elect a majority (or any) directors, limiting traditional accountability mechanisms.

Public Benefit Corporation Status, Controlled-Company Status, and Anti-Takeover Provisions

Anthropic will retain its PBC status post-IPO, explicitly allowing directors to balance shareholder interests with the public benefit mission (responsible AI development).[9]

• New/Updated Details: PBC charter maintained; LTBT and founder voting provide de facto control resembling a “controlled company” (concentrated influence over board and key matters, though not formally labeled as such in reports). Anti-takeover elements include LTBT board majority + notice requirements, founder Class F voting, and PBC flexibility to prioritize mission over pure profit maximization. A supermajority stockholder vote (reported as high as 85% in some coverage) could potentially alter the structure as a “kill switch.”[10][4]
• Implication: Entrants face a governance moat that prioritizes long-term mission alignment over short-term shareholder returns, potentially deterring or complicating activist or takeover strategies.

Use of Proceeds, Offering Size/Price Range, Underwriters, Directed Share Programs, and Lockup Terms

Detailed terms remain unavailable publicly due to the confidential filing status.[11]

• New/Updated Details (Oct 2026 reports): No confirmed offering size, price range, share count, or use of proceeds (expected to support growth, compute infrastructure, R&D). Reported underwriters (from leaks): Morgan Stanley and Goldman Sachs as leads; JPMorgan and Citigroup in the syndicate. No specific information on directed share programs or lockup terms (length, staged releases, exceptions) in recent sources. Potential valuation discussed in $1.5T–$2T range (with some reports noting possible downward adjustment from earlier $2T+ targets).[12][13]
• Implication: Without public terms, precise capital structure impacts (e.g., dilution, insider sales post-lockup) cannot be assessed; monitor for the public S-1 for these details.

Additional Recent Mission/Equity Commitment (Oct 18, 2026 Announcement)

Anthropic announced (subject to stockholder approval) committing 5% of shares to a new wholly owned Anthropic Public Benefit Fund (LLC structure for flexibility), with board discretion to add 2% more for every 50% valuation increase above a baseline. Combined with founders’ prior 80% personal equity donation pledges and employee match programs, this brings ~20% of shares dedicated to public good (AI safety, biomedical research, nonprofit discounts, potential direct distributions; explicitly not for lobbying/politics). Further governance and milestone details forthcoming.[14][15]

These elements represent the primary new or updated information from the last several months. The structure emphasizes mission protection alongside founder control, which will likely draw significant investor and regulatory attention upon public filing. For the most current terms, await the public S-1.